Glaxo Grp England Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GLAXO GRP ENGLAND, and when can generic versions of GLAXO GRP ENGLAND drugs launch?
GLAXO GRP ENGLAND has one approved drug.
There are seven US patents protecting GLAXO GRP ENGLAND drugs.
There are ninety-three patent family members on GLAXO GRP ENGLAND drugs in thirty-seven countries and twenty-eight supplementary protection certificates in sixteen countries.
Summary for Glaxo Grp England
International Patents: | 93 |
US Patents: | 7 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Glaxo Grp England
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 7,498,440 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 8,201,556 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 9,333,310 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 8,309,572 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 7,488,827 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Glaxo Grp England
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | 5,873,360 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Glaxo Grp England Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2577248 | ⤷ Try a Trial |
Poland | 1740177 | ⤷ Try a Trial |
United Kingdom | 0418278 | ⤷ Try a Trial |
Norway | 2017017 | ⤷ Try a Trial |
Eurasian Patent Organization | 200601991 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Glaxo Grp England Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2506844 | LUC00077 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
1740177 | 14C0075 | France | ⤷ Try a Trial | PRODUCT NAME: BROMURE D'UMECLIDINIUM; REGISTRATION NO/DATE: EU/1/14/922 001-003 20140428 |
1740177 | 58/2014 | Austria | ⤷ Try a Trial | PRODUCT NAME: UMECLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922 (MITTEILUNG) 20140430 |
1740177 | C01740177/02 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014 |
1740177 | C20140032 00132 | Estonia | ⤷ Try a Trial | PRODUCT NAME: UMEKLIDIINBROMIID;REG NO/DATE: EU/1/14/922 30.04.2014 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.